Navigation Links
New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
Date:5/30/2008

Gene Expression Profiling of Tumor is Correlated With Clinical Response

CHICAGO, May 30 /PRNewswire-FirstCall/ -- New data presented by GlaxoSmithKline (GSK) today highlighted the potential of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) through results of three studies evaluating highly targeted immunotherapy as a treatment for metastatic melanoma and non-small cell lung cancer (NSCLC). These data were presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract Nos: 9065(1), 9045(2) and 7501(3)).

A randomized, open label Phase II study designed to evaluate two different formulations of the MAGE-A3 ASCI in patients with metastatic melanoma has been conducted. In this study, the ASCI, which is a combination of MAGE-A3 recombinant protein and a GSK proprietary Adjuvant System, was evaluated and resultant data suggest a positive trend for clinical response. These data also demonstrate the induction of a desirable immune response, including humoral and cellular responses. These study results represent a second positive trend for clinical activity for the novel MAGE-A3 cancer immunotherapeutic, following encouraging clinical results reported in a separate double-blind, placebo-controlled Phase II study of patients with NSCLC(4). The encouraging results from the Phase II NSCLC study have led to a Phase III safety and efficacy trial in MAGE-A3-positive NSCLC patients (stage IB, II and IIIA) who have undergone complete surgical resection (MAGRIT; MAGE-A3 Adjuvant Non-Small Cell LunG CanceR ImmunoTherapy).

At this year's ASCO, GSK also presented data regarding the use of the genetic profiling of melanoma in predicting clinical outcomes of treatment with MAGE-A3 ASCI. Biopsies performed on the melanoma tumors prior to immunization were used to identify genetic markers expressed by the disease. These markers enabled researchers to establish a correlation between the expression
'/>"/>

SOURCE GlaxoSmithKline (GSK)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Presentation of Data on Progens Cancer Epigenetic Targets Platform
2. Genmab Announces Updates on Phase III Cancer Studies
3. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
6. Prostate Cancer Treatment Offers Results Without Side Effects
7. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
8. First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer
9. Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy
10. Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center
11. Ovarian Cancer Vaccine Clinical Trial Begins at Cancer Treatment Centers of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year. Reported sales decreased 4% ... quarter. , Net earnings per diluted share as ... prior-year period. Adjusted EPS was $2.80 , an ...
(Date:7/30/2015)... , July 30, 2015 IRIDEX Corporation ... release its second quarter 2015 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, August ... quarter and other business developments. Interested parties ...
(Date:7/30/2015)... 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® and t:flex™ Insulin Pumps, today ... Agreements with Dexcom, Inc. to allow the integration ... Dexcom G5 and G6 continuous glucose monitoring ("CGM") ... platform with Dexcom,s future CGM systems is an ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... NEW YORK, Jan. 11, 2011 WebMD Health Corp. (Nasdaq: ... private placement of $400 million aggregate principal amount of 2.50% ... of notes pursuant to the exercise in full of the ... qualified institutional buyers pursuant to Rule 144A under the Securities ...
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: ... in the development, assembly, marketing and sale of medical ... that it will participate in the Arab Health Exhibition ... 2011 at the Dubai World Trade Centre in Dubai, ...
Cached Medicine Technology:WebMD Closes Offering of 2.50% Convertible Notes Due 2018 2Dehaier Medical Announces Participation in Arab Health 2011 2
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe , a ... redesigned website at Healthpointe.net. The new website will feature a sleek and streamlined ... serves to provide smoother interactions between patients and the Healthpointe clinics and ensures ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ZH Healthcare ... OSEHRA 2015. , What is HITaaS? Health IT as a Service (HITaaS) is a ... software as a service (SaaS). , HITaaS manages all aspects of ...
(Date:7/31/2015)... ... 31, 2015 , ... EB Medicine, leading publisher of clinical ... pleased to announce that it has partnered with AgileMD to release Pediatric ... and Android smartphones and tablets. , “The April 2015 launch of our ...
(Date:7/31/2015)... VA (PRWEB) , ... July 31, 2015 , ... The ... U.S. Rep. Michael Burgess, MD, (R-Tex) presenting “What’s Next for Health Care: A View ... a physician and founder of the Congressional Health Caucus, Rep. Burgess has a special ...
(Date:7/31/2015)... ... July 31, 2015 , ... Super-Sod wants to participate in planning new home ... as the perfect fit for such a goal. Houzz is a social media ... is a dynamic site that spreads home and home garden design ideas when members ...
Breaking Medicine News(10 mins):Health News:Healthpointe Announces Newly Redesigned Website 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3Health News:Super-Sod Created a Landscape Profile on Houzz.com for Home Garden Design 2
... Don't get misled by the looks of freeze-dried fruits. ... that the antioxidant phytochemicals //that is present in fresh ... benefits of these dried fruits are assimilated easily into ... into this project, Gary Stoner, Ph.D., Professor and Chair ...
... a report it was found that Botswana has one of ... that about 81children //were abused in various forms between January ... the children were brutally beaten some were subjected to rape, ... not reported as the victim’s family opted for an out ...
... in protected and hygienic environments are more susceptible to ... ,Duke University Medical Center researchers investigated this ... to this case. They have identified why people in ... allergy and autoimmune diseases than do people in opposite ...
... Bioinformatics, a tool used to develop human disease research, now ... extremely //complex virus - the vaccinia virus, which is used ... Institute for Allergy & Immunology (LIAI). ,Researchers ... who have used it to successfully predict immune response to ...
... India open to acting in B'wood Sydney, Sabrina Houssami, ... Australia in the Miss World contest, says she is open ... non-Australian parentage to win the Miss Australia title last month, ... Lebanese father. ,Sabrina, who supports a charity called ...
... the medical journal Pediatrics, a single dose of chicken pox ... in schools. ,Dr. Sandra L. Snow and colleagues from ... outbreak of chicken pox at one of the schools. They ... had not suffered chicken and had taken the vaccination, and ...
Cached Medicine News:Health News:Protected Environment v/s Unprotected Affect Hygiene Health Immunity 2Health News:Protected Environment v/s Unprotected Affect Hygiene Health Immunity 3Health News:Protected Environment v/s Unprotected Affect Hygiene Health Immunity 4Health News:Bioinformatics Made a Boon In Immune Response Study - LIAI Finds 2Health News:Bioinformatics Made a Boon In Immune Response Study - LIAI Finds 3
...
... features an advanced design that accommodates both ... gives surgeons the flexibility to easily customize ... is built-in to every aspect of the ... Secure-Twist anti-migration system to the screw options ...
... is designed to meet the clinical challenges ... attached locking mechanism and the choice of ... variable angle screws for ease of implantation ... plate system allows the surgeon the versatility ...
... Revolutions start with small things. ... is one of the trailblazers of ... reflecting the,trend towards ever smaller access ... the operation site. ,The HiLAN XS ...
Medicine Products: